Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
27.75 USD | -0.11% | +0.18% | -3.61% |
Mar. 28 | Pfizer, Astellas' Combination Therapy Application For Bladder Cancer Accepted in China | MT |
Mar. 28 | Beijing Outlook, Ex-Dividend Dates Roil Asian Stock Markets | MT |
Financials (USD)
Sales 2024 * | 59.91B | Sales 2025 * | 63B | Capitalization | 157B |
---|---|---|---|---|---|
Net income 2024 * | 7.81B | Net income 2025 * | 12.7B | EV / Sales 2024 * | 3.39 x |
Net Debt 2024 * | 45.61B | Net Debt 2025 * | 42.35B | EV / Sales 2025 * | 3.17 x |
P/E ratio 2024 * |
18.5
x | P/E ratio 2025 * |
12.2
x | Employees | 88,000 |
Yield 2024 * |
6.13% | Yield 2025 * |
6.29% | Free-Float | 59.09% |
Latest transcript on Pfizer, Inc.
1 day | -0.11% | ||
1 week | +0.18% | ||
Current month | +4.48% | ||
1 month | +3.20% | ||
3 months | -3.01% | ||
6 months | -13.55% | ||
Current year | -3.61% |
Managers | Title | Age | Since |
---|---|---|---|
Albert Bourla
CEO | Chief Executive Officer | 62 | 92-12-31 |
David Denton
DFI | Director of Finance/CFO | 59 | 22-05-01 |
Jeff Settleman
CTO | Chief Tech/Sci/R&D Officer | - | 19-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 66 | 20-03-31 | |
Ronald Blaylock
BRD | Director/Board Member | 64 | 17-02-22 |
Shantanu Narayen
BRD | Director/Board Member | 60 | 13-09-26 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
14.74% | 227 M€ | +6.28% | - | |
9.37% | 18 M€ | +7.01% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 27.75 | -0.11% | 39,613,279 |
24-03-27 | 27.78 | +0.69% | 34,247,616 |
24-03-26 | 27.59 | +0.58% | 38,220,263 |
24-03-25 | 27.43 | +0.26% | 31,110,645 |
24-03-22 | 27.36 | -1.08% | 28,830,115 |
Delayed Quote Nyse, March 28, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-3.61% | 157B | |
+33.46% | 701B | |
+26.24% | 571B | |
+0.93% | 381B | |
+21.03% | 334B | |
+17.51% | 319B | |
+0.74% | 210B | |
+2.95% | 210B | |
-6.05% | 201B | |
-1.28% | 153B |